Patents by Inventor Maria Calderon-Cacia
Maria Calderon-Cacia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11034759Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: October 12, 2018Date of Patent: June 15, 2021Assignees: Novartis Vaccines and Diagnostics, Inc., Xoma Technology Ltd.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20190263900Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: October 12, 2018Publication date: August 29, 2019Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20180171009Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: February 7, 2018Publication date: June 21, 2018Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Patent number: 9926371Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: November 9, 2016Date of Patent: March 27, 2018Assignees: NOVARTIS VACCINES AND DIAGNOSTICS, INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20170152311Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: November 9, 2016Publication date: June 1, 2017Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Patent number: 9522186Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: June 3, 2015Date of Patent: December 20, 2016Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20160015809Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: June 3, 2015Publication date: January 21, 2016Applicants: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Patent number: 9079956Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: GrantFiled: February 3, 2014Date of Patent: July 14, 2015Assignees: NOVARTIS VACCINES AND DIAGNOSTICS INC., XOMA TECHNOLOGY LTD.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20140242071Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: February 3, 2014Publication date: August 28, 2014Applicants: XOMA TECHNOLOGY LTD., NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
-
Publication number: 20120231526Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided.Type: ApplicationFiled: March 27, 2012Publication date: September 13, 2012Inventors: John M. Polo, Catherine Greer, Maria Calderon-Cacia, Daniel De La Vega, JR., Thomas W. Dubensky, JR.
-
Patent number: 7807430Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: March 3, 2008Date of Patent: October 5, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
-
Publication number: 20100055128Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. in one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.Type: ApplicationFiled: September 18, 2008Publication date: March 4, 2010Applicant: Novartis Vaccines and Diagnostics IncInventors: John M. Polo, Catherine Greer, Maria Calderon-Cacia, Daniel De La Vega, JR., Thomas W. Dubensky, JR.
-
Publication number: 20090324604Abstract: M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.Type: ApplicationFiled: January 6, 2005Publication date: December 31, 2009Applicants: CHIRON CORPORATION, XOMA Technology Ltd.Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory M. Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Arnold Horwitz, Maria Calderon-Cacia
-
Publication number: 20080182313Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: March 3, 2008Publication date: July 31, 2008Applicant: Novartis Vaccines and Diagonstics, Inc.Inventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 7361484Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: February 8, 2007Date of Patent: April 22, 2008Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Publication number: 20070249004Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: February 8, 2007Publication date: October 25, 2007Applicant: Chiron CorporationInventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
-
Patent number: 7195886Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: December 10, 2003Date of Patent: March 27, 2007Assignee: Chiron CorporationInventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
-
Patent number: 7135321Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: October 20, 2003Date of Patent: November 14, 2006Assignee: Chiron CorporationInventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
-
Publication number: 20060088932Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: December 10, 2003Publication date: April 27, 2006Applicant: Chiron CorporationInventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
-
Publication number: 20050112752Abstract: Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics.Type: ApplicationFiled: June 29, 2004Publication date: May 26, 2005Applicant: Chiron CorporationInventors: John Polo, Catherine Greer, Maria Calderon-Cacia, Daniel De La Vega, Thomas Dubensky